Infectious Disease · Medical Literature
Treatment of Recurrent C. difficile Infection - Making the Best Use of What We Have.
Clinical relevance
Recurrent Clostridioides difficile infection (rCDI) affects up to 25–35% of patients after initial antibiotic therapy and carries a 50–60% risk of further recurrence with each subsequent episode, representing a major source of infectious disease morbidity, rehospitalization, and mortality (>20,000 U.S. deaths annually). Despite the availability of fidaxomicin and microbiota-based therapies, more than 66% of clinicians globally still use standard vancomycin regimens for CDI treatment, creating a critical evidence gap around optimal antibiotic sequencing and duration. This NEJM Evidence editorial contextualizes a head-to-head RCT comparing vancomycin taper-and-pulse (31 days) versus fidaxomicin (10 days) versus standard vancomycin (10 days) for rCDI — providing urgently needed comparative data to guide antibiotic selection in this high-burden population. NOTE: Full editorial abstract was unavailable; key findings are drawn from the companion RCT and closely related supporting evidence.
Key findings
1. In the companion TAPER-V RCT (N=275, 12 Canadian hospitals), the 4-week vancomycin pulse-and-taper regimen reduced rCDI at day 38 to 6.7% vs. 15.4% with the standard 2-week pulse regimen (adjusted RR 0.43; 95% CrI 0.19–0.89), corresponding to a 99% posterior probability of superiority for early recurrence prevention. 2. At the primary endpoint of day 56, rCDI occurred in 14.8% of vancomycin taper recipients vs. 17.7% of standard-pulse recipients (aRR 0.84; 95% CrI 0.48–1.45), representing a 73.8% posterior probability of superiority — a clinically meaningful but statistically inconclusive trend, partly due to early trial termination. 3. In phase 3 RCT data (fidaxomicin vs. vancomycin 10-day, N=629), fidaxomicin reduced rCDI from 25.3% to 15.4% in the mITT analysis (P=0.005; RR reduction ~39%), with clinical cure rates equivalent between arms (88.2% vs. 85.8%). 4. Meta-analysis data (8 RCTs, 1,951 patients) demonstrated fidaxomicin superiority over vancomycin for recurrence at 40 days (RR 0.52; 95% CI 0.38–0.70), 60 days (RR 0.38; 95% CI 0.21–0.69), and 90 days (RR 0.62; 95% CI 0.50–0.77), with no significant difference in all-cause mortality at 40 days. 5. Fidaxomicin showed superior long-term all-cause mortality benefit over vancomycin at >60 days (RR 0.57; 95% CI 0.34–0.96, P=0.03), though no significant 40-day mortality difference was detected. 6. The TAPER-V trial was terminated early due to lower-than-anticipated recurrence rates in both arms; no significant differences in all-cause mortality (aRR 3.91; 95% CrI 0.44–34.50) or hospital readmission (aRR 0.82; 95% CrI 0.48–1.38) were observed between regimens, and adverse events were rare and mild (nausea 3.0%, abdominal discomfort 2.3% in the taper group).
Practice implications
For patients with first or recurrent CDI who cannot access fidaxomicin due to cost or availability — a barrier affecting over two-thirds of clinicians internationally — a 4-week vancomycin pulse-and-taper regimen (125 mg QID ×14 days, then BID ×7 days, then QD ×7 days) should be considered as an evidence-informed alternative, given its demonstrated reduction in early recurrence (day 38 NNT ≈ 12) with a favorable safety profile. For higher-risk patients (age ≥65, immunocompromised, prior rCDI, concurrent systemic antibiotic exposure), fidaxomicin (200 mg BID ×10 days) remains the preferred antibiotic agent given its superior recurrence reduction across multiple time points and a possible long-term mortality advantage. Clinicians should recognize that standard 10-day vancomycin alone is insufficient for recurrence-prone patients, and escalation to taper-and-pulse vancomycin or fidaxomicin, followed by consideration of microbiota-based therapies (VOWST, REBYOTA, or conventional FMT) after antibiotic completion in patients with ≥2 recurrences, represents current best evidence for breaking the cycle of rCDI.